Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kylo-01
- Development stage
- Unknown
- Lead developer
- Kylonova Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Kylo-01 is a small interfering RNA (siRNA) therapeutic candidate developed by Kylonova (Xiamen) Biopharma for the treatment of liver-related metabolic diseases, specifically non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The drug utilizes Kylonova's proprietary Nano-Lipid Particle Delivery Platform (NPDP), which encapsulates the siRNA in multi-lipid nanoparticles to ensure stability in the bloodstream and efficient delivery to target liver cells. By leveraging the RNA interference (RNAi) mechanism, Kylo-01 is designed to silence specific genes involved in the pathogenesis of NASH, thereby reducing liver inflammation and steatosis. As of early 2026, the candidate is in the preclinical development stage.
02
Targets
LPA (Lysophosphatidic acid)
Beyond the preview
Go deeper on Kylo-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kylo-01.